Sermorelin is a synthetic analog of GHRH(1-29) — the first 29 amino acids of endogenous growth hormone-releasing hormone. In women, GH secretion is higher in amplitude but more variable than in men, and is strongly influenced by estrogen status and cycle phase. Sermorelin research in female subjects focuses on restoring age-related GH decline while preserving the body's own feedback regulation.
Female GH Physiology and Sermorelin
Women naturally secrete more GH per pulse than men, but pulse frequency and amplitude decline with age and with the estrogen withdrawal of menopause. Sermorelin stimulates the pituitary to release GH in a pulsatile, physiological pattern — preserving the hypothalamic-pituitary axis feedback loop rather than bypassing it with exogenous GH.
Research Dosage Considerations
Female research protocols commonly use 100–300 mcg administered subcutaneously at bedtime. Lower starting doses (100 mcg) are typical to assess tolerability before any titration. Because sermorelin stimulates the pituitary rather than replacing GH directly, it preserves the body's own feedback regulation.
Timing and the Growth Hormone Pulse
Sermorelin is dosed at night, at least 2–3 hours after the last meal, because elevated blood glucose and insulin blunt GH release. Fasted bedtime administration aligns the induced pulse with the body's natural nocturnal GH surge, which is the rationale behind evening-only protocols.
Reported Research Applications
In female subjects, sermorelin research focuses on body composition, skin quality and collagen support, sleep architecture, and recovery — outcomes tied to restoring youthful GH/IGF-1 signaling. All of these applications are investigational; sermorelin is a research compound, not an approved therapy for these uses.
Safety and Hormonal Context
Because sermorelin works through the body's own regulatory axis, its side-effect profile is generally milder than direct growth hormone administration. Research still monitors IGF-1 levels, glucose tolerance, and injection-site reactions. Since estrogen status materially affects GH sensitivity, hormonal context is a key research variable in female subjects.